AKT is activated by phosphorylation at both Thr-308 and Ser-473 sites26, which activates downstream proteins to promote resistance to the EGFR inhibitor gefitinib in lung cancer patients27,28. The gene discussed is EGFR; the disease is lung carcinoma.